Postmortem prolactin as a marker of antemortem stress

T J Jones, M J Hallworth

Abstract
Aim—To determine whether raised prolactin concentrations could be identified using postmortem venous blood and whether the level of prolactin correlated with antemortem stress.

Methods—Blood was obtained from the right femoral vein of 100 random adult necropsy cases, all of whom had been dead less than four days. Prolactin was determined in the samples by microparticle immunoassay. The levels of prolactin obtained were then analysed in relation to sex and cause of death, with particular emphasis on a history of antemortem stress and drug use.

Results—Prolactin in all cases of trauma was in the normal range (up to 500 mU/l). In cases of sudden unexpected deaths the mean concentration was 533 mU/l (95% confidence interval (CI), 372 to 694 mU/l). Postoperative deaths or cases with chronic disease had a mean value of 1027 mU/l (95% CI, 735 to 1319 mU/l). Cases of suicide had a mean value of 1398 mU/l. Analysis of the suicides by sex showed a significant difference, the mean in female cases being 2072 mU/l compared with 692 mU/l in male cases. In three of the four female suicides with the highest prolactin, the hyperprolactinaemia might have been attributable to a drug effect, but one case still had unexplained hyperprolactinaemia.

Conclusions—It is possible to detect prolactin reliably in postmortem venous blood samples. Prolactin values at necropsy differ according to the cause of death, with markedly higher values in postoperative deaths and in the chronically ill. Hyperprolactinaemia in cases of suicide is likely to result from the effects of the drugs used, but the levels were higher than previously reported.

(J Clin Pathol 1999;52:749–751)

Keywords: postmortem prolactin; antemortem stress; suicide

Prolactin is a single chain polypeptide produced by the anterior pituitary gland with a molecular weight of 23 000 daltons, although it may occur in 50 kDa and 150 kDa variants which are not biologically active. Its physiological role is in the initiation and maintenance of lactation, although the plasma concentrations in non-lactating females and males are very similar.

Prolactin has a biological half life of 20 minutes but is stable in vitro for up to seven days at room temperature. No previous studies have been done to determine whether prolactin can be detected in postmortem blood samples.

The causes of hyperprolactinaemia are numerous. Physiological causes are pregnancy, breast feeding, nipple and breast stimulation, sleep, and exercise. Pathological causes include stress such as hypoglycaemia, surgery, myocardial infarction, and epilepsy; pituitary and hypothalamic disease interfering with central inhibitors of prolactin secretion; drugs, particularly dopamine blockers, methyldopa, oestrogens, opiates, tricyclic antidepressants, cimetidine, and verapamil. Some medical disorders such as hypothyroidism, chronic renal failure, and cirrhosis may also cause a marked increase in prolactin levels.

Previous studies have indicated a link between psychological stress and hyperprolactinaemia but there have been no postmortem studies of cases of suicide to determine whether the antemortem psychological stress before self harm is associated with increased plasma prolactin at necropsy. No studies have been done to determine whether antemortem physical stress can be detected by raised postmortem prolactin.

The aims of this study were therefore to determine whether plasma prolactin could be measured in blood taken at necropsy, whether the level of prolactin correlated with a history of antemortem physical stress, and whether prolactin is increased in cases of fatal self harm. This would be useful if there was doubt about the interval between physical insult and death and in cases of suicide it would alert the investigator to the possibility of a drug overdose.

Methods
Blood was sampled from the right femoral vein at 100 adult necropsy examinations. Cases with known pituitary disease or with pituitary abnormalities found at necropsy were excluded. Before evisceration, an incision was made over the right femoral vein and the blood was removed by venepuncture. This was then analysed using an Abbott AxSym automated analyser. The working assay range was 15–4800 mU/l and no “high dose hook effect” occurs below 240 000 mU/l. Dilution of serum samples showed acceptable parallelism. The assay was standardised against the WHO third international standard 84/500. In studies performed by the kit manufacturer, the mean recovery of added prolactin from human serum was 95.4%.

Full necropsy reports were available on all cases and these were then inspected for the antemortem clinical and drug history,
The highest levels of prolactin were found in male victims; this difference was statistically significant (p = 0.0140). The mean prolactin in postoperative deaths and those from chronic medical conditions was clearly raised compared with 692 mU/l in cases showing that female victims had a mean prolactin concentration of 2072 mU/l (95% CI, 735 to 1319 mU/l).

In sudden unexpected deaths from diseases of the cardiovascular system mean prolactin concentration was just above normal (533 mU/l; 95% confidence interval (CI), 372 to 694 mU/l).

Mean prolactin in postoperative deaths and those from chronic disease was clearly raised (1027 mU/l; 95% CI, 735 to 1319 mU/l).

Analysis of prolactin level by sex in suicide cases showed that female victims had a mean value of 2072 mU/l compared with 692 mU/l in male victims; this difference was significant (p < 0.05) (fig 2).

The causes of death in female suicide cases and their prolactin levels are shown in table 1. The highest levels of prolactin were found in drug related deaths; the case of hanging with a level of 3981 mU/l was an exception, although in this case the woman was taking hormone replacement therapy. The three other cases of female hanging had a mean prolactin concentration of 518 mU/l.

The remaining female suicide case died of carbon monoxide poisoning and had a prolactin concentration of 2852 mU/l. This could not be attributed to any identifiable drug effect.

### Results

Six of the 100 samples were haemolysed and thus unsuitable for analysis. Of the remaining 94 cases, 17 died from trauma, 19 were sudden cardiac death, 42 were postoperative or caused by chronic medical conditions, and 16 were suicides. Figure 1 shows the prolactin concentrations in relation to the cause of death.

The mean prolactin in cases of suicide was 1398 mU/l (normal up to 500 mU/l) compared with 777 mU/l in the non-suicides. This difference was statistically significant (p = 0.0140). In all cases of death from trauma prolactin was within the normal range. Analysis of the necropsy reports in these cases showed that death occurred at or very soon after the traumatic event. In sudden unexpected deaths from diseases of the cardiovascular system mean prolactin concentration was just above normal (533 mU/l; 95% confidence interval (CI), 372 to 694 mU/l).

### Discussion

In this study we showed that it is possible to measure prolactin in postmortem venous blood and to identify hyperprolactinaemia. The level of prolactin found was roughly comparable with the duration of antemortem physical stress, cases of death from trauma, where death was very rapid, having a normal prolactin level. With sudden cardiac events, where death is often not so rapid, the mean prolactin was just above normal, presumably because in some cases the delay between onset of symptoms and death has allowed a stress response to develop. The postoperative deaths and those from chronic medical conditions had a mean value well above normal, indicating that in this group a stress response was well developed, with a consistently raised prolactin.

Some cases of suicide have significantly raised values, although on further analysis this may be attributable to drug effects (for example, codeine, dextropropoxyphene, or paracetamol induced liver necrosis), although the levels found in this study were greater than those previously described in living volunteers. In addition, one individual had hyperprolactinaemia that could not be attributable to any known drug effect.

There is therefore some support in this study for the hypothesis that antemortem psychological stress such as depression produces hyperprolactinaemia identifiable postmortem. Cases with physical stress had a raised prolactin and this may therefore be a useful adjunct to forensic investigation when the possible length of survival after a traumatic event is unclear.

### Table 1  Cause of death in female cases of suicide and level of prolactin

<table>
<thead>
<tr>
<th>Cause of death</th>
<th>Prolactin (mU/l)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Co-proxamol and dihydrocodeine overdose</td>
<td>4034</td>
</tr>
<tr>
<td>Paracetamol overdose</td>
<td>1813</td>
</tr>
<tr>
<td>Co-proxamol overdose</td>
<td>2341</td>
</tr>
<tr>
<td>CO poisoning</td>
<td>2852</td>
</tr>
<tr>
<td>Hanging</td>
<td>3981</td>
</tr>
<tr>
<td>Hanging</td>
<td>809</td>
</tr>
<tr>
<td>Hanging</td>
<td>462</td>
</tr>
<tr>
<td>Hanging</td>
<td>283</td>
</tr>
</tbody>
</table>


**Royal College of Pathologists**

Forthcoming symposia to be held at 2 Carlton House Terrace, London SW1:

**Pulmonary pathology:** 7 October 1999

**Understanding stillbirth—is there progress?** 20 October 1999

**Genomics in therapy and xenotransplantation: safety and ethics:** 24 November 1999

**Cytopathology update. Searching for cancer:** 14 December 1999

**Can’t give a cause of death—won’t give a cause of death:** 12 January 2000

**Molecular genetics of solid tumours: translating research into clinical practice:** 24 February 2000

**Managing immunodeficiency:** 22 March 2000

**Histopathology update: GI and hepatobiliary update and controversies:** 13–14 April 2000

These meetings are open to members and non-members of the college. Further details and application forms from:

Scientific Meetings Officer, RCPath, 2 Carlton House Terrace, London SW1Y 5AF, UK; tel +44 (0)171 930 5862, ext 24/25; fax +44 (0)171 321 0523.
Postmortem prolactin as a marker of antemortem stress.

T J Jones and M J Hallworth

J Clin Pathol 1999 52: 749-751
doi: 10.1136/jcp.52.10.749

Updated information and services can be found at:
http://jcp.bmj.com/content/52/10/749

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/